In this free webinar, learn about the evolving field of radiopharmaceuticals in cancer treatment. Attendees will gain insight into the key challenges and complexities of radiopharmaceutical trials.

For more information, or to register for this event, visit A Rare Look into New Guidances: The Future State of Orphan Drug Development.

A new community hub at Orchard Park in Cambridge has opened and charities hope it will help break down barriers to help people access support. The Core community centre was opened by students at ...

Fintel reports that on February 4, 2025, Wolfe Research initiated coverage of Vera Therapeutics (NasdaqGM:VERA) with a ...

Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) had its price objective lifted by equities researchers at JPMorgan Chase & Co. from $51.00 to $53.00 in a report issued on Tuesday,Benzinga ...

Wolfe Research initiated coverage of Vera Therapeutics (VERA) with an Outperform rating and $49 price target The firm is ...

Subin Baral, EY global life sciences deals leader, told GEN M&A deals are expected to increase in 2025, driven by biopharmas that are eager to recoup revenues they expect to lose as their aging ...

Issues like increased noise, air pollution and traffic often arise, raising concerns about the impact of industrial parks on ...

Check the time stamp on this data. Updated AI-Generated Signals for Vera Therapeutics Inc. (VERA) available here: VERA. Type ...

Goldman Sachs has initiated coverage of Vera Therapeutics (VERA) with a buy rating, citing its drug candidate atacicept and a ...

Goldman Sachs analyst Paul Choi initiated coverage of Vera Therapeutics (VERA) with a Buy rating and $58 price target Following the recent ...

Shares of Vera Therapeutics, Inc. (NASDAQ:VERA – Get Free Report) have received a consensus recommendation of “Buy” from the nine brokerages that are presently covering the firm, Marketbeat reports.